Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AKBA's Cash to Debt is ranked higher than
84% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. AKBA: No Debt )
AKBA' s 10-Year Cash to Debt Range
Min: 2713   Max: 12424.6
Current: No Debt

2713
12424.6
Z-Score: 21.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -41.41
AKBA's ROE (%) is ranked higher than
72% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. AKBA: -41.41 )
AKBA' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -41.41

ROA (%) -39.27
AKBA's ROA (%) is ranked higher than
69% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. AKBA: -39.27 )
AKBA' s 10-Year ROA (%) Range
Min: -71.35   Max: -71.35
Current: -39.27

ROC (Joel Greenblatt) (%) -28908.62
AKBA's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. AKBA: -28908.62 )
AKBA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106220   Max: -106220
Current: -28908.62

» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.12
AKBA's P/B is ranked higher than
90% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. AKBA: 2.12 )
AKBA' s 10-Year P/B Range
Min: 0   Max: 9.5
Current: 2.12

0
9.5
Current Ratio 18.37
AKBA's Current Ratio is ranked higher than
94% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AKBA: 18.37 )
AKBA' s 10-Year Current Ratio Range
Min: 8.57   Max: 26.43
Current: 18.37

8.57
26.43
Quick Ratio 18.37
AKBA's Quick Ratio is ranked higher than
95% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AKBA: 18.37 )
AKBA' s 10-Year Quick Ratio Range
Min: 8.57   Max: 26.43
Current: 18.37

8.57
26.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.16
AKBA's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. AKBA: 2.16 )
AKBA' s 10-Year Price/Net Cash Range
Min: 3.14   Max: 4.85
Current: 2.16

3.14
4.85
Price/Net Current Asset Value 2.16
AKBA's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. AKBA: 2.16 )
AKBA' s 10-Year Price/Net Current Asset Value Range
Min: 3.14   Max: 4.85
Current: 2.16

3.14
4.85
Price/Tangible Book 2.12
AKBA's Price/Tangible Book is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. AKBA: 2.12 )
AKBA' s 10-Year Price/Tangible Book Range
Min: 3.1   Max: 4.77
Current: 2.12

3.1
4.77
Earnings Yield (Greenblatt) -27.10
AKBA's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. AKBA: -27.10 )
AKBA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -37   Max: 0
Current: -27.1

-37
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 19 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 18 2014
Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index Dec 15 2014
Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index Dec 15 2014
Annual Changes to the NASDAQ Biotechnology Index Dec 15 2014
Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 04 2014
Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan Nov 17 2014
Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan Nov 17 2014
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week... Nov 11 2014
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week... Nov 11 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
Akebia Announces Third Quarter 2014 Financial Results Nov 10 2014
Akebia to Participate in Upcoming Investor Conferences Oct 31 2014
Akebia to Participate in Upcoming Investor Conferences Oct 31 2014
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis... Oct 27 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 27 2014
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis... Oct 27 2014
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis... Oct 27 2014
Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia... Sep 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK